Cannabidiol Exerts Anticonvulsant Effects Alone and in Combination with Δ9-THC through the 5-HT1A Receptor in the Neocortex of Mice
Cells · 2024
DOI: 10.3390/cells13060466 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Yasaman Javadzadeh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Krembil Research Institute, University Health Network, Toronto, ON M5S 0T8, Canada. Hauptthemen laut MEDLINE: Cannabidiol, Cannabinoids, Neocortex. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mitacs, Ontario Centre of Innovation, Mitacs./Avicanna Inc..
Abstract (Originalsprache)
Cannabinoids have shown potential in drug-resistant epilepsy treatment; however, we lack knowledge on which cannabinoid(s) to use, dosing, and their pharmacological targets. This study investigated (i) the anticonvulsant effect of Cannabidiol (CBD) alone and (ii) in combination with Delta-9 Tetrahydrocannabinol (Δ9-THC), as well as (iii) the serotonin (5-HT)1A receptor’s role in CBD’s mechanism of action. Seizure activity, induced by 4-aminopyridine, was measured by extracellular field recordings in cortex layer 2/3 of mouse brain slices. The anticonvulsant effect of 10, 30, and 100 µM CBD alone and combined with Δ9-THC was evaluated. To examine CBD’s mechanism of action, slices were pre-treated with a 5-HT1A receptor antagonist before CBD’s effect was evaluated. An amount of ≥30 µM CBD alone exerted significant anticonvulsant effects while 10 µM CBD did not. However, 10 µM CBD combined with low-dose Δ9-THC (20:3 ratio) displayed significantly greater anticonvulsant effects than either phytocannabinoid alone. Furthermore, blocking 5-HT1A receptors before CBD application significantly abolished CBD’s effects. Thus, our results demonstrate the efficacy of low-dose CBD and Δ9-THC combined and that CBD exerts its effects, at least in part, through 5-HT1A receptors. These results could address drug-resistance while providing insight into CBD’s mechanism of action, laying the groundwork for further testing of cannabinoids as anticonvulsants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Krembil Research Institute, University Health Network, Toronto, ON M5S 0T8, Canada.
- Institute of Biomedical Engineering, University of Toronto, Toronto, ON M5S 1A1, Canada.
- Avicanna Inc., Toronto, ON M5G 1V2, Canada.
- Department of Medicine (Neurology), University Health Network, Toronto, ON M5G 2C4, Canada.
ORCID-Profile: Yasaman Javadzadeh, Alexandra Santos, Peter L Carlen
Förderung
- Mitacs
- Ontario Centre of Innovation
- Mitacs./Avicanna Inc.
- Ontario center of innovation
Zitieren
APA
Javadzadeh, Y., Santos, A., Aquilino, M. S., Mylvaganam, S., Urban, K., & Carlen, P. L. (2024). Cannabidiol Exerts Anticonvulsant Effects Alone and in Combination with Δ9-THC through the 5-HT1A Receptor in the Neocortex of Mice. Cells. https://doi.org/10.3390/cells13060466
Vancouver
Javadzadeh Y, Santos A, Aquilino MS, Mylvaganam S, Urban K, Carlen PL. Cannabidiol Exerts Anticonvulsant Effects Alone and in Combination with Δ9-THC through the 5-HT1A Receptor in the Neocortex of Mice. Cells. 2024. doi:10.3390/cells13060466
BibTeX
@article{Javadzadeh2024,
author = {Javadzadeh, Yasaman and Santos, Alexandra and Aquilino, Mark S and Mylvaganam, Shanthini and Urban, Karolina and Carlen, Peter L},
title = {Cannabidiol Exerts Anticonvulsant Effects Alone and in Combination with Δ9-THC through the 5-HT1A Receptor in the Neocortex of Mice},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13060466}
}
EUVIMED